an ocular syndrome has been reported associated with the use of topiramate - the syndrome is characterised by acute myopia and secondary angle-closure glaucoma
as of August 17, 2001, there had been 23 reported cases of this ocular syndrome; 22 in adults and 1 in a paediatric patient. This information was base on the post marketing experience in more than 825,000 patients (1)
symptoms of ocular syndrome generally occur within 1 month of the start of treatment and include decreased visual acuity and/or ocular pain. Ophthalmological findings include hyperaemia, bilateral myopia, anterior chamber shallowing, and increased intra-ocular pressure with or without mydriasis. Also there may also be supraciliary effusion resulting in anterior displacement of lens and iris. Treatment includes discontinuation of topiramate treatment as rapidly as is clinically feasible and appropriate measures to reduce intraocular pressure
please consult summary of product characteristics for more details
Reference:
(1) Janssen-Cilag Ltd (15/10/2001). Letter - Important Safety Information - Topamax (R) Tablets and Topamax (R) Sprinkle Capsules (Topiramate).
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page